ArticleResearch square2025

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.

Wungki Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.